Jeffrey Sonnenfeld

"Arvin Krishna of IBM and tech titans would meet with him in small groups. It was extremely effective... the CEOs of Walmart, Home Depot and Costco went and met with Trump privately." Trump responds well to private, backstage diplomacy rather than public defiance or massive lobbying groups. Companies whose leadership understands this specific hub-and-spoke engagement model can successfully negotiate favorable terms and avoid his public wrath. LONG. These companies have demonstrated the political savvy required to navigate Trump's unorthodox leadership style, minimizing their regulatory risks while quietly advancing their corporate interests. Trump's ad-hoc decision-making and reliance on loyalists over experts could still unpredictably impact trade or tech policies before these CEOs have a chance to intervene.

"Arvin Krishna of IBM and tech titans would meet with him in small groups. It was extremely effective... the CEOs of Walmart, Home Depot and Costco went and met with Trump privately." Trump responds well to private, backstage diplomacy rather than public defiance or massive lobbying groups. Companies whose leadership understands this specific hub-and-spoke engagement model can successfully negotiate favorable terms and avoid his public wrath. LONG. These companies have demonstrated the political savvy required to navigate Trump's unorthodox leadership style, minimizing their regulatory risks while quietly advancing their corporate interests. Trump's ad-hoc decision-making and reliance on loyalists over experts could still unpredictably impact trade or tech policies before these CEOs have a chance to intervene.

"Arvin Krishna of IBM and tech titans would meet with him in small groups. It was extremely effective... the CEOs of Walmart, Home Depot and Costco went and met with Trump privately." Trump responds well to private, backstage diplomacy rather than public defiance or massive lobbying groups. Companies whose leadership understands this specific hub-and-spoke engagement model can successfully negotiate favorable terms and avoid his public wrath. LONG. These companies have demonstrated the political savvy required to navigate Trump's unorthodox leadership style, minimizing their regulatory risks while quietly advancing their corporate interests. Trump's ad-hoc decision-making and reliance on loyalists over experts could still unpredictably impact trade or tech policies before these CEOs have a chance to intervene.

"The Trump RX plan of course is developed by these private meetings with the pharma types... especially Merc and Eli Lily and J&J have been very effective at that." Companies that engage Trump privately and collectively can shape policy in their favor without triggering his public attacks. The pharmaceutical sector successfully used this playbook to navigate drug pricing policies, resulting in a plan that was much better for the industry than critics anticipated. LONG. These large pharma companies have proven they can manage political and regulatory risk under Trump by using private, collective influence to protect their margins. The presence of RFK Jr. in the administration is noted as a "pernicious problem" that could introduce unpredictable regulatory or narrative risks for the sector.

"The Trump RX plan of course is developed by these private meetings with the pharma types... especially Merc and Eli Lily and J&J have been very effective at that." Companies that engage Trump privately and collectively can shape policy in their favor without triggering his public attacks. The pharmaceutical sector successfully used this playbook to navigate drug pricing policies, resulting in a plan that was much better for the industry than critics anticipated. LONG. These large pharma companies have proven they can manage political and regulatory risk under Trump by using private, collective influence to protect their margins. The presence of RFK Jr. in the administration is noted as a "pernicious problem" that could introduce unpredictable regulatory or narrative risks for the sector.

"The Trump RX plan of course is developed by these private meetings with the pharma types... especially Merc and Eli Lily and J&J have been very effective at that." Companies that engage Trump privately and collectively can shape policy in their favor without triggering his public attacks. The pharmaceutical sector successfully used this playbook to navigate drug pricing policies, resulting in a plan that was much better for the industry than critics anticipated. LONG. These large pharma companies have proven they can manage political and regulatory risk under Trump by using private, collective influence to protect their margins. The presence of RFK Jr. in the administration is noted as a "pernicious problem" that could introduce unpredictable regulatory or narrative risks for the sector.

"The Trump RX plan of course is developed by these private meetings with the pharma types... especially Merc and Eli Lily and J&J have been very effective at that." Companies that engage Trump privately and collectively can shape policy in their favor without triggering his public attacks. The pharmaceutical sector successfully used this playbook to navigate drug pricing policies, resulting in a plan that was much better for the industry than critics anticipated. LONG. These large pharma companies have proven they can manage political and regulatory risk under Trump by using private, collective influence to protect their margins. The presence of RFK Jr. in the administration is noted as a "pernicious problem" that could introduce unpredictable regulatory or narrative risks for the sector.

"Arvin Krishna of IBM and tech titans would meet with him in small groups. It was extremely effective... the CEOs of Walmart, Home Depot and Costco went and met with Trump privately." Trump responds well to private, backstage diplomacy rather than public defiance or massive lobbying groups. Companies whose leadership understands this specific hub-and-spoke engagement model can successfully negotiate favorable terms and avoid his public wrath. LONG. These companies have demonstrated the political savvy required to navigate Trump's unorthodox leadership style, minimizing their regulatory risks while quietly advancing their corporate interests. Trump's ad-hoc decision-making and reliance on loyalists over experts could still unpredictably impact trade or tech policies before these CEOs have a chance to intervene.